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Background: Calcifediol (25D) availability is crucial for calcitriol (1,25D) synthesis, but regulation of vitamin
D hydroxylases ismajorly responsible for 1,25D synthesis. The net efﬁciency of vitaminD hydroxylasesmight be
informative. We assume that the ratio between calcitriol and calcifediol (25D/1,25D) serum concentrations
could suggest the vitamin D hydroxylation efﬁciency.
Methods:We evaluated 25D/1,25D in different patient populations: hemodialysis (HD, n = 76), CKD stage 2–5
(n = 111), renal transplant (TX, n = 135), patients with no renal disease (No-CKD, n = 290), and primary
hyperparathyroidism (PHP, n = 20).
Results: The geometric mean of 1,25D/25D (pg/ng) averaged 1.11 (HD), 1.36 (CKD), 1.77 (TX), 2.22 (No-CKD),
and 4.11 (PHP), with a progressive increment from HD to PHP (p-value for the trend b0.001). Each clinical
condition elicited a signiﬁcant effect on 25D/1,25D (p b 0.0001) and adjusted multivariate analysis indicated
levels of Cas, Ps, PTH, and 25D as predictors of 25D/1,25D. Both in vitamin D deﬁcient and replete subjects
(25Db or≥20 ng/ml) 25D/1,25D associatedwith each clinical condition (p b 0.0001) andmean values increased
progressively from HD to PHP (p-values for the trend b0.0001). Regression analysis between 25D (substrate)
and 25D/1,25D (efﬁciency) revealed an exponential negative correlation in No-CKD (r2Exp = 0.53, p b 0.001)
with sharp increments of 25D/1,25D when 25D values are b20 ng/ml. At variance, in CKD (r2lin = 0.19)
and in TX (r2lin = 0.32) the regression was linear as if, in case of deﬁcit, some inhibition of the system
were operating.
Conclusion and General signiﬁcance: In conclusion 1,25D/25D can reﬂect the efﬁciency of vitamin D hydrox-
ylases more than separate evaluation of 25D and 1,25D and can facilitate the therapeutic choices in different
patient populations.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Circulating levels of 1,25-dihydroxyvitamin D (1,25D or calcitriol) are
predominantly regulated within a very narrow, picomolar range by three
enzymes of the cytochrome P450 family. The activity of hepatic 25-
hydroxylase (CYP27A1, 25-OH-ase) is substrate dependent (i.e., induced
by the availability of cholecalciferol) and is not inhibited by the nanomolar
concentrations of its product, 25-hydroxycholecalciferol (25D or
calcifediol) [1]. In contrast, the variable activity of the ubiquitously
expressed 1-α-hydroxylase (CYP27-B1, 1-α-OH-ase) is substrateular, Respiratory, Nephrologic,
rsity of Rome, Nephrology and
a, 1668, 041100 Latina, Italy.
azzaferro).
. This is an open access article underindependent and tightly regulated by several hormones and substances,
including calcitriol itself, the concentrations of which exert a negative
feedback [2,3]. The third enzyme, 24-hydroxylase (CYP24-A1, 24-OH-
ase), which is similarly diffuse among numerous tissues, appears to be
regulated by those same factors that activate 1-α-OH-ase but in the op-
posite direction. Thus, this enzyme represents a powerful catabolic
pathway for both the active hormone and its precursor [4,5]. In summa-
ry, it is the interplay among these three enzymes, which are regulated
by several factors (Fig. 1), that determines the physiologicalﬂuctuations
of calcitriol and calcitroic acid within the picomolar range and of the
other metabolites within the nanomolar range. [1,6,7].
The role played by the regulation of this enzymatic machinery
during pathological conditions can be appreciated with two clinical
examples. First, during the earliest phase of chronic kidney disease
(CKD) 1,25D levels start to rapidly decrease signiﬁcantly prior to any
crucial reduction of the nephronmass that might explain a quantitativethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Several factors affect the activity of Vitamin D hydroxylases, resulting in signiﬁcantly different concentrations of circulating metabolites.
252 M. Pasquali et al. / BBA Clinical 3 (2015) 251–256reduction of 1-α-OH-ase availability [8–10]. Importantly, even sub-
strate (calcifediol) levels decrease, but this drop occurs later, during
more advanced stages of the disease [11]. In fact, the early reduction
of 1,25D is now considered as a secondary event to the inhibition
of 1-α-OH-ase and the stimulation of 24-OH-ase by ﬁbroblast growth
factor 23 (FGF23), the novel phosphate-regulating hormone, the levels
of which increase prior to any reduction of 1,25D [12]. In contrast, in
primary hyperparathyroidism (PHP), circulating calcitriol levels in-
crease as a result of PTH-dependent stimulation of 1-α-OH-ase activity.
It is interesting to consider that FGF23 levels also increase during PHP
[13,14], possibly as a secondary response of bone to limit increases in
1,25D [13,15]. Even in this case, the relationship with the substrate,
25D, is weak [16].
These two examples illustrate how calcitriol levels are regulated
by complex hormonal interplays (in the examples of FGF23 and PTH,
with opposite effects on vitamin D hydroxylases) and how the ﬁnal
balance is only partially dependent on substrate availability. According-
ly, it is conceivable that in some patients, 25D levels are normal, but its
conversion to calcitriol is impaired. In contrast, in other patients, 25D
levels might be low, but the rate of conversion to 1,25D is increased.
From a clinical perspective, patients with the ﬁrst condition might be
at increased risk for vitamin D deﬁciency compared to those with the
second condition because even increased 25D levels may not guarantee
adequate amounts of the active metabolite, calcitriol. Accordingly, the
ability to accurately estimate the net efﬁciency of the vitaminD synthet-
ic pathwaymight be informative in the context of various clinical condi-
tions, such as those requiring a choice between active or inactive
vitamin D supplements, those requiring evidence for the administration
of drugs that interfere with the pathway in speciﬁc patient populations,
or simply to evaluate a different approach at quantifying vitamin D sta-
tus in epidemiological studies.
The aim of our study was to evaluate whether it is possible to
describe and to estimate the efﬁciency of vitamin D hydroxylation by
considering the ratio between the concentrations of circulating levels
of calcitriol (the active hormone) and calcifediol (the substrate). The ar-
bitrary unit obtained (pg/ng) can represent approximately how many
picograms of calcitriol are produced per nanogram of available 25D.
To verify this hypothesis, we calculated the ratio values and examined
the behaviour of this ratio in different patient populations exhibiting
hypothetically diverse efﬁciency.2. Methods
2.1. Subjects
In this study, we enrolled eligible patients from the outpatient units of
our hospitals. Theywere subjectswhowere referred for the possible pres-
ence of kidney disease or to control their suspected or known clinical con-
ditions of isolated urinary abnormalities, hypertension, nephrolithiasis,
CKD (either on conservative or on maintenance haemodialysis) or renal
transplantation (TX). Inclusion criteria were designated as follows: the
ability to give written informed consent; age 18–80 years; no evidence
of acute underlying illness; and noprevious therapywith active or natural
vitamin D metabolites for at least three months. Exclusion criteria were
designated as follows: active treatment with drugs known to interfere
with vitamin D synthesis, with the exception of immunosuppressive
drugs for TX patients. Fasting blood samples were obtained in all partici-
pants in order to measure serum levels of creatinine, Ca, P, PTH, 25D and
1,25D. To uniformly dilute the impact of 25D season-related shifts, blood
samples were collected randomly over one year (between January and
December 2010), according to casual ambulatory controls. The presence
of proteinuria was evaluated by standard fasting urine tests. Clinical
parameters and prescribed therapies were recorded for each patient. For
the purpose of this study, we considered the following ﬁve different
populations: patients on maintenance haemodialysis (HD); patients
with CKD stage 2–5 (proteinuria N 150 mg/dl and eGFR b 90 ml/min/
1.73m2 conﬁrmed in at least twomeasurements at a six-month interval);
renal TX patients (TX = any level of eGFR or proteinuria plus stable
clinical condition and transplant at least 6 months prior to enrolment);
subjects with no evidence of chronic kidney damage or divalent ion
abnormalities (No-CKD= no proteinuria or kidney structural abnormal-
ities, eGFR N 90 ml/min/1.73 m2, corrected serum Ca b 10.2 mg/dl and
PTH b 65 pg/ml); and patients with clinical and biochemical evidence of
primary hyperparathyroidism (PHP = corrected serum Ca N 10.5 mg/dl,
PTH levels N 70 pg/ml and history of nephrolithiasis).
3. Assays
Serum creatinine (kinetic alkaline picrate method), Ca
(cresolphthalein-complexone method), and P (ammonium molybdate
method) levels were assayed by routine, standard colorimetric
Table 1
Main clinical and biochemical parameters of the ﬁve populations.
HD CKD 2–5 TX No-CKD PHP
N° 76 111 135 290 20
Age, y 64 ± 15 63 ± 15 51 ± 11 45 ± 13.8 50 ± 17
M/F 43/34 72/39 79/56 146/141 9/11
eGFR, ml/min // 36.4 ± 22 46.98 ± 19.17 112 ± 13.9 88 ± 34
Time on HD, y 4.32 ± 4.64 // // // //
Time on Tx, y // // 5.7 ± 5.1 // //
Ca, mg/dl 8.7 ± 0.8 9.2 ± 0.7 9.75 ± 0.86 9.4 ± 0.29 11 ± 0.52
P, mg/dl 4.86 ± 1.39 3.7 ± 1 3.3 ± 0.8 3.1 ± 0.54 3 ± 0.58
PTH, pg/ml 262 ± 286 98 ± 103 82.1 ± 113 439 ± 14.6 163 ± 82
25D, ng/ml 12.26 ± 7.7 19.5 ± 13.3 25.4 ± 13.8 25.35 ± 13.3 17 ± 12
1,25D, pg/ml 11.9 ± 4.9 27 ± 18 44.5 ± 24.6 50.4 ± 16.6 67 ± 33
Fig. 2. Progressive increase of the ratio (geometric means, 95% CI) in HD to PHP
patients (p-value trend b0.0001). HD and CKD had non-signiﬁcantly different values.
(*) = Increased ratio values in TX compared to HD (p b 0.0001) and CKD (p b 0.01)
patients. (#) = Increased values of the ratio in No-CKD compared to HD (p b 0.0001),
CKD (p b .0001) and TX (p b 0.007) patients. (&) = Increased values of the ratio in PHP
compared to HD (p b 0.0001), CKD (p b 0.0001), TX (p b 0.0001) and No-CKD
(p b 0.0003) patients.
253M. Pasquali et al. / BBA Clinical 3 (2015) 251–256techniques using a routine analyser. Glomerular ﬁltration rate (GFR)
was estimated according to the Modiﬁcation of Diet in Renal Disease
(MDRD) Study formula. PTHwas assayed using an immunoradiometric
technique (DiaSorin, Stillwater, MN, USA) based on a double antibody
probing of the intact molecule; our normal values were within the
range of 10–55 pg/mL, with intra- and inter-assay variations of 6.5
and 9.8%, respectively. Levels of 25D were assayed using a commercial
kit (DiaSorin, Stillwater, MN, USA) that included sample puriﬁcation
with acetonitrile followed by an 125I-based radioimmunoassay. Intra-
and inter-assay coefﬁcients of variation were 10.8 and 9.4%, respective-
ly. Levels of 1,25Dweremeasured using a radioimmunoassay according
to themanufacturer's protocols (IDS Ltd, Boldon, UK), which included a
monoclonal immune-extraction followed by quantitation using a stan-
dard 125I-based radioimmunoassay. Intra- and inter-assay coefﬁcients
of variation were b12 and b14%, respectively. The normal range ob-
served in our laboratory was between 19.5 and 67.0 pg/mL. The
1,25D/25D ratio was calculated based on values of calcitriol (pg/ml)
and calcifediol (ng/ml), which resulted in arbitrary units of pg/ng that
should indicate howmany pg of calcitriol are produced per ng of circu-
lating calcifediol.
4. Statistical analysis
Statistical analysis was performed using R software version 2.15.3.
The data are expressed as mean values ± SD. The data were log-
transformed and consequently reported as geometric means (with
95% conﬁdence intervals) when necessary. When the normality as-
sumption was not tenable, F or Kruskal–Wallis statistics were used to
test for any signiﬁcant differences. When the F or Kruskal–Wallis statis-
tic was signiﬁcant, Bonferroni's adjusted pairwise comparisons were
used to compare groups in pairs. The presence of trend effects was ver-
iﬁed using the Jonckheere–Terpstra test. Multivariate regression analy-
sis was applied to estimate the predictive parameters of the 1,25D/25D
ratio and to account for the role of the different variables considered.
The optimal multivariate regressionmodel was selected using stepwise
forward regression based on optimisation of the Akaike information
criterion.
5. Results
5.1. Subject characteristics
Of the 632 total enrolled patients, 76 were on HD, 111 were CKD
stage 2–5 on conservative therapy, 135 were TX with eGFR stage 1–5,
290 were No-CKD, and 20 presented with PHP. The main clinical and
biochemical parameters of the ﬁve groups of subjects are reported in
Table 1. On average, HD (64 ± 15 years old) and CKD (63 ± 15 years
old.) patients were older than TX (51 ± 11 years old) and PHP (50 ±
17 years old) patients, whereas the No-CKD patients were the youngest
(45 ± 13 years old). Male subjects were numerically more prevalent in
all but the PHP group.Vitamin D status, as reﬂected by 25D levels, was more favourable
in the No-CKD (25D = 25.35 ± 13.30 ng/ml) and TX (25D = 25.4 ±
13.8 ng/ml) patients and less favourable in the HD (12.26 ±
7.7 ng/ml) patients. The levels of 1,25D indicated, on average, a progres-
sive increment from HD (11.9 ± 4.9 pg/ml) to CKD (27 ± 18), TX
(44.5 ± 24.6), No-CKD (50.4 ± 16.6) and PHP (67 ± 33) patients.
Given the skewed distribution, we log-transformed the values of
25Dand 1,25D for further statistical analysis and found that the twome-
tabolites were positively correlated with each of the clinical conditions
(Spearman correlation analysis: HD, r = 0.51, p b 0.001; CKD, r =
0.51, p b 0.001; No-CKD, r = 0.45, p b 0.001; TX, r = 0.25, p b 0.003;
and PHP, r = 0.47, p b 0.038).
5.2. 1,25D/25D ratio
As illustrated in Fig. 2, the geometricmean (95%CI) of the 1,25D/25D
ratio averaged 1.11 (0.96–1.28) pg/ng in HD, 1.36 (0.98–1.89) pg/ng in
CKD, 1.77 (1.28–2.44) pg/ng in TX, 2.22 (1.64–3.00) pg/ng in No-CKD,
and 4.11 (2.60–6.48) pg/ng in PHP patients, with a signiﬁcant and pro-
gressive increment from HD to PHP (p-value for the trend b0.001).
In univariate analyses, each of the clinical conditions elicited a signif-
icant effect on the ratio (p b 0.0001), themean geometric values ofwhich
did not differ between CKD andHDbutwere signiﬁcantly increased in TX
(vs HD, p b 0.0001; vs CKD, p b 0.01), No-CKD (vs HD, p b 0.0001; vs CKD,
Table 2
Multivariate analysis performed to identify predictors of 1,25D/25D ratio.
Coef C.I. p
Ca, mg/dl 1.183 1.112–1.258 0.000
P, mg/dl −0.888 0.848–0.930 0.000
PTH, pg/ml −0.968 0.938–0.999 0.042
25D, ng/ml −0.967 0.964–0.970 0.000
254 M. Pasquali et al. / BBA Clinical 3 (2015) 251–256p b 0.0001; vs TX, p b 0.007), and in PHP (vs HD, p b 0.0001; vs CKD,
p b 0.0001; vs Tx, p b 0.0001; vs No-CKD, p b 0.0003) patients (Fig. 2).
Adjusted multivariate analysis, performed without the eGFR param-
eter (due to its strict correlation with the different clinical conditions)
indicated that the optimal estimate of the 1,25D/25D ratio was obtained
by serum levels of Ca, P, PTH, and 25D levels in each of the clinical
conditions (Table 2). Based on this analysis, we estimated using HD as
the reference that after adjusting for the predictive variables (i.e., Ca,
P, PTH and 25D), the ratio was increased by 20, 60, 100 and 135% in
CKD (p b 0.018), TX (p b 0.0001), No-CKD (p b 0.0001), and PHP
(p b 0.0001) patients, respectively.
The role of eGFR on the ratio was next evaluated in a multi-
regression analysis, which only included CKD and TX patients, given
that they exhibited comparable ranges of renal function. After adjusting
for sex, eGFR, Ca, P, and 25D, the TX patients exhibited signiﬁcantly
higher ratio values (p = 0.0044).
The role of PTH on the ratio was further analysed separately in pa-
tients with (HD, CRF, Tx) or without chronic renal failure (No-CKD).
We found a positive correlation in No-CKD (r = 0.127; p = 0.030)
with an inﬂection point of 0.915 in the PTH interval between 32 and
45 ng/ml. In chronic renal failure patients the correlation was negative
(r =−0.161; p = 0.0286) with an inﬂection point of 1.28 in the PTH
interval between 77 and 95 pg/ml.
5.3. 1,25D/25D ratio and vitamin D status
To evaluate the effect of vitamin D status, we separately consid-
ered subjects with or without vitamin D deﬁciency (25D values b
or ≥20 ng/ml).
In cases of vitamin D deﬁciency, univariate analysis conﬁrmed the
association between the ratio and each clinical condition (p b 0.0001),
as well as a similar and progressive increment of mean values from
HD to PHP (p-values for the trend b0.0001), (Fig. 3A). The values didFig. 3. [A] Progressive increase of the ratio (geometric mean, 95% CI) in vitamin D-deﬁcient HD
patients. (*) = Increased values of the ratio in TX, No-CKD and PHP (no differences among the
crease of the ratio (geometric mean, 95% CI) in vitamin D-replete HD to PHP (p trend b0.0001)
values of the ratio in TX, No-CKD and PHP (no difference among them) compared to HD (p b 0not differ between HD (1.3 pg/ng, 95% CI 1.1–1.5) and CKD (1.6 pg/ng,
95% CI 1.1–2.3) patients, whereas they were signiﬁcantly increased in
TX (2.9 pg/ng, 95% CI 2.0–4.3), No-CKD (3.5 pg/ng, 95% CI 2.5–4.9) and
PHP (4.5 pg/ng, 95% CI 2.8–7.3) patients (p b 0.001). However, no differ-
ences were detected among the latter three populations (Fig. 3A). In
vitamin D-replete (25D ≥ 20 ng/ml) subjects, the average ratio values
in each population were invariably lower than that observed in the cor-
responding vitamin D-depleted subjects (Fig. 3, B). The clinical condi-
tion was associated with the ratio, which increased with a positive
trend effect from HD to PHP (p b 0.0001, Fig. 3B). The mean values did
not differ between HD (0.6 pg/ng, 95% CI 0.5–0.8) and CKD (1.1 pg/ng,
95% CI 0.6–1.8; p = n.s. vs HD) patients but increased signiﬁcantly
(p b 0.001) in TX (1.4 pg/ng, 95% CI 0.8–2.4), No-CKD (1.7 pg/ng, 95%
CI 1.0–2.8) and PHP (2.8 pg/ng, 95% CI 1.2–6.2) patients, again with no
difference among the latter three groups (Fig. 3B).
Adjusted multivariate analysis in vitamin D-deﬁcient cases revealed
a predictive role of each disease condition and of serum Ca, P, PTH and
25D levels, whereas for vitamin D-replete subjects, the role of age, Ca,
P and 25D were predictive. During vitamin D deﬁciency, by taking HD
as reference and after adjusting for the respective predictive variables,
the ratio was marginally increased in CKD (+15%, p = n.s.) patients
and signiﬁcantly increased in TX (+80%; p b 0.0001), No-CKD
(+120%; p b 0.0001) and PHP (+106%; p b 0.0001) patients
(Table 3). However, in vitamin D-replete cases, the ratio was increased
by 62, 95, 146, and 261% in CKD (pb 0.0001), TX (pb 0.0001), inNo-CKD
(p b 0.0001) and in PHP (p b 0.0001) patients (Table 3).
Lastly, as illustrated in Fig. 4, regression analysis revealed a signiﬁcant
negative correlation between25D (substrate) and the ratio (efﬁciency) in
each clinical condition considered (in this analysis, we excluded PHP due
to the low number of cases). Importantly, the goodness of ﬁt test indicat-
ed an exponential shape in HD (r2lin = 0.41 vs r2Exp = 0.59; p b 0.001)
and No-CKD (r2lin= 0.40 vs r2Exp= 0.53, p b 0.001) patients and a linear
shape in CKD (r2lin=0.19 vs r2Exp=0.18, p=n.s.) and in TX (r2lin=0.32
vs r2Exp = 0.33, p = n.s.) patients.
6. Discussion
Numerous epidemiological observations amongdifferent pathological
conditions [17–20] and demographics [21–24] describe the association
between Vitamin D deﬁciency and increased mortality. The plausibility
of this association is based on the fact that theVitaminD receptor exhibits
a widespread expression pattern in the human body and that activeto PHP (p trend b0.0001) patients. Non-signiﬁcantly different values between HD and CKD
m) patients compared to HD (p b 0.001) and CKD (p b 0.001) patients. [B] Progressive in-
patients. Non-signiﬁcantly different values between HD and CKD patients. (*)= Increased
.001) and CKD (p b 0.001) patients.
Table 3
Percent increase of the ratio compared toHDpatients (reference), in eachof the separately
studied populations in Vitamin D-depleted or -repleted cases. The increase observed in
Vitamin D-depleted CKD patients did not signiﬁcantly differ from that observed in HD
patients.
Subjects with 25D b 20 ng/ml Subjects with 25D N 20 ng/ml
CKD 2–5 +15 +62
TX +80 +95
No-CKD +120 +146
PHP +103 +261
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cellular signalling pathways. In these epidemiological studies, Vitamin D
status has been predominantly evaluated by levels of 25D, or less fre-
quently, 1,25D. However, calcitriol and calcifediol are characterised by
different biological properties, and their concentrations are only weakly
correlated [8,25].Moreover, the physiological complexity of the synthetic
pathway of this vitamin suggests that the efﬁcient regulation of vitaminD
hydroxylation might be more crucial than the concentration of any D
metabolite alone.
Data from our study indicate that the 1,25D/25D ratio, which theo-
retically represents how many picograms of calcitriol are produced
per nanogram of circulating calcifediol, can be indicative of the efﬁcien-
cy of vitamin D hydroxylation. Indeed, the 1,25D/25D ratios were quite
different among patient populations exhibiting anticipated differences
in the efﬁciency of hydroxylation and, as expected, increased progres-
sively from HD to CKD, TX and No-CKD, with peak values in patients
with PHP. In multivariate analysis PTH was a powerful predictor of the
ratio. Interestingly, in separate populations, the correlation between
PTH and 1,25D/25D ratio was positive in No-CKD patients and negative
in those with any type of CRF (HD, TX, CRF). Thus, in No-CKD the posi-
tive correlation reﬂects the expected stimulus of PTH on hydroxylase
efﬁciency, while in renal failure PTH increases to tentatively restore
the declined efﬁciency of hydroxylases. Furthermore, vitamin D status
affected the ratio in the most anticipated manner. In fact, compared to
vitamin D deﬁciency, vitamin D repletion resulted in lower values,
invariably in each of the clinical conditions considered. Notably, the
progressive increment of the ratio persisted even in case of substrate
deﬁcit clearly underlining the role of different hydroxylation efﬁciencyFig. 4. Exponential negative relationship between 25D and the ratio in HD and No-CKin these sub-populations. The lowest absolute values were observed,
at ﬁrst glance surprisingly, in the absence of deﬁciency in HD patients
but these patients cannot be expected to substantially increase circulat-
ing levels of calcitriol from damaged kidneys simply because of sub-
strate availability. In comparison, replete CKD patients exhibited a
hydroxylation efﬁciency that, on average, did not signiﬁcantly differ
from HD patients, suggesting that the system is blunted in spite of
some residual renal function. Accordingly, we would anticipate limited
efﬁcacy of supplemental therapies with inactive products in these two
populations. Interestingly, our analysis, which adjusted for eGFR, indi-
cated that vitamin D hydroxylation is less blunted in TX compared to
CKD patients, a ﬁnding possibly explained either by the different types
of secondary hyperparathyroidism in these populations or by the effects
of immunosuppressive therapy on the TX patients. Consistent with our
results, a recent study on dialysis patients found no change in the intes-
tinal absorption of Ca after 3months of 20,000 IU/week of cholecalcifer-
ol therapy before the normalisation of 25D and improvement of 1,25D
levels [26]. In further studies, no effect on bonemetabolism parameters
was evident following cholecalciferol supplementation of dialysis pa-
tients [27], whereas in renal transplant patients, replacement therapy
with cholecalciferol reduced PTH levels [28].
Moving from quantitative data to qualitative behaviour, regression
analysis between 25D levels and the 1,25D/25D ratio can theoretically
describe the response of hydroxylation to progressive vitamin D deple-
tion; this analysis indicated a negative linear trend in CKD and TX
patients and a negative but exponential regression in No-CKD and, un-
expectedly, in HD patients. If we consider the behaviour in the No-
CKD population as a reference, it is evident from our data that the expo-
nential increment begins when 25D levels decline below 20 ng/ml,
consistent with the most commonly adopted threshold for deﬁciency.
In CKDand TXpatients, the qualitative response is hampered, consistent
with ensuing or persistent SH conditions, respectively. As per the unex-
pected results suggesting that HDpatients behave asNo-CKDpatients, it
is evident from the data that the ratio invariably averages signiﬁcantly
lower values in HD patients compared to any other group and that the
exponential increment is observed only when 25D values are approxi-
mately undetectable (b5 ng/ml). Assuming that the contribution of
renal hydroxylation is trivial in HD patients, we can hypothesise that
in this case, the ratio is reﬂective of the efﬁciency of extra-renal calcitriol
synthesis. It would be interesting to conﬁrm this last observationD patients, compared to the linear regression observed in CKD and TX patients.
256 M. Pasquali et al. / BBA Clinical 3 (2015) 251–256in anephric patients in whom the circulating calcitriol levels are, by def-
inition, of exclusive extra-renal origin.
Taken together, we propose that the ratio of 1,25D/25D can be
considered as representative of vitamin D hydroxylation efﬁciency
and, as such, can be useful as a different approach at evaluating vitamin
D status in various populations of patients, including those not exam-
ined in this study. For example, for patientswith systemic inﬂammatory
diseases, such as lupus nephritis, who have been reported to experience
worse prognosis in the presence of low 25D levels [20] andwho are sug-
gested to beneﬁt from vitamin D replacement therapy, the ratio values
might help to guide reasoned choices between natural or active metab-
olites. In anephric patients, as mentioned above, the ratio might reﬂect
the efﬁciency of the extra-renal synthetic pathway independently of
actual circulating calcitriol levels (undoubtedly a topic of investigative
interest). In transplant patients, the ratio might be helpful to evaluate
whether different immunosuppressive regimens elicit diverse effects
on vitamin D metabolism.
We acknowledge that our study has several limitations. First, it is
purely speculative. However, the potential clinical implications are in-
triguing, and it would be interesting to verify our ﬁndings with further
studies in different patient populations. Second, we did not assay other
vitamin Dmetabolites, in particular the catabolic 24-hydroxylated com-
pounds, although this could have added precision to our evaluation.
However, experience with the assessment of 24-hydroxylated metabo-
lites remains limited to few research centres. Third, we performed a sin-
gle sampling; it would have been important to conﬁrm the data inmore
than one assay in the same subject to discern the extent of variability.
Overall, however, the number of patients that we enrolled cannot be
regarded as low, and the results described are consistent with current
pathophysiological concepts. Fourth, we did not include anephric
patients to verify the occurrence of the lowest values of the ratio.
Fifth, we did not evaluate the correlation between the ratio and other
parameters like intestinal calcium absorption, bone mineral density
and mortality.
In conclusion, our data indicate that the ratio of 1,25D/25D can
reﬂect the efﬁciency of vitamin D hydroxylation. Determination of the
ratio ismore optimal than the separate evaluation of the twomost com-
monly assayed metabolites and could facilitate the estimation of how
efﬁciently the vitamin D system is working to maintain the picomolar
amounts of active metabolite required for the expected biological ef-
fects. This helpful information could facilitate the elucidation of speciﬁc
treatment parameters or rational therapeutic choices in different pa-
tient populations.
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